Passive Antibodies Other Than Anti-D Through RhIG?

 RhIG and its many brand names (Rhophylac, WinRho, RhoGAM, etc) is derived from human blood plasma containing the anti-D antibody. Plasma is harvested from healthy Rh negative donors who are intentionally alloimmunized with with the RhD antigen. Those with an active immune response will create Anti-D in 1 to 2 weeks time. The donor can then provide plasma to RhIG manufacturers to create the RhIG Anti-D drug. The donors may even need to be re-stimulated with Rh positive cells to produce more antibody. 

These alloimmunization events give rise to the chance for OTHER red cell antibodies to be formed as well. If given enough vials of RhIG it is absolutely possible to see these antibodies reflected in the antibody screen of an RhIG recipient. We see a positive screen for the Anti-D (as a passive anti-D) so why not for a Kell? C? Jka? It's possible and it has happened. 

Take for instance a patient that needed a six vial injection of RhIG due to a Fetomaternal Hemorrhage. The RhIG vials were quantified via Kleihauer Bekte stain. The next antibody screen performed on this patient showed not only a passive Anti-D but ALSO an Anti-C. It is unlikely, given how quickly the reactivity manifested, that this was due to true alloimmunization. The RhIG package insert was consulted, and it does indeed say passive transfer of other non Anti-D antibodies is also possible, especially anti-C. Package inserts of many other RhIG brands have information like this with some claiming the possibility of passive Kell, passive Kidd, passive Duffy, etc. The patient had Passive Anti-C placed in there file, and a note to follow up 6 months down the road for an additional antibody screen. 

This presents a challenge for those in need of transfusion support, because even though the patient may not be truly creating the antibody, they likely should receive antigen negative blood until the RhIG has been removed from circulation. The more vials given per event, the more likely we are to come across this scenario. A pre-event antibody screen could be helpful in determining passive vs alloantibody. 

Read More

ADAMTS13 has logged into the chat...

What Is ADAMTS13?

ADAMTS13 stands for “A Disintegrin and Metalloproteinase with a Thrombospondin Type 1 Motif, Member 13.”

If you can't remember that, von Willebrand factor-cleaving protease gets the point across considerably faster.

It also sounds suspiciously like someone's old AIM screen name. I wouldn't be surprised if ADAMTS13 is already taken on PathLabTalk.

ADAMTS13 is an enzyme that regulates the size and activity of von Willebrand factor (VWF) multimers. VWF plays a critical role in platelet adhesion, particularly under the high shear conditions found in small blood vessels.

Newly released VWF can form very large, highly adhesive multimers. Under shear stress, portions of VWF unfold and expose a cleavage site within the A2 domain. ADAMTS13 cleaves these ultralarge VWF multimers into smaller, less thrombogenic forms.

Without adequate ADAMTS13 activity, ultralarge VWF multimers remain in circulation and can bind platelets excessively. The result is formation of platelet-rich microthrombi throughout the small vasculature.

This produces two characteristic problems:

• Thrombocytopenia, as platelets are consumed in the microthrombi

• Microangiopathic hemolytic anemia (MAHA), as red blood cells are mechanically damaged while passing through affected small vessels

The microvascular thrombosis can also cause ischemic injury to organs, particularly the brain, heart, kidneys, and gastrointestinal tract.

Despite the often extremely low platelet count, spontaneous bleeding is not usually the dominant clinical problem in TTP. The major danger is widespread microvascular thrombosis and resulting organ injury.

TTP and Severe ADAMTS13 Deficiency

Severe ADAMTS13 deficiency is the defining laboratory abnormality of thrombotic thrombocytopenic purpura (TTP).

An ADAMTS13 activity of less than 10% of normal in the appropriate clinical setting strongly supports the diagnosis of TTP and helps distinguish it from other thrombotic microangiopathies.

Ideally, the specimen for ADAMTS13 activity and inhibitor testing should be collected before plasma therapy or therapeutic plasma exchange begins, since donor plasma contains ADAMTS13 and can alter the result.

However, TTP is a medical emergency. When clinical suspicion is high, treatment should not be delayed while waiting for the ADAMTS13 result.

TTP can broadly be divided into two forms:

Immune TTP

The majority of TTP encountered clinically is immune-mediated TTP (iTTP).

In iTTP, autoantibodies target ADAMTS13. These antibodies can directly inhibit ADAMTS13 activity, increase its clearance from circulation, or do both.

The resulting severe ADAMTS13 deficiency allows ultralarge VWF multimers to persist, promoting uncontrolled platelet adhesion and microvascular thrombosis.

Congenital TTP

A much rarer form, congenital TTP (cTTP), results from pathogenic variants in the ADAMTS13 gene that cause severe inherited ADAMTS13 deficiency.

Congenital TTP has historically also been called Upshaw-Schulman syndrome.

Unlike immune TTP, there is no underlying anti-ADAMTS13 autoantibody driving the disease. The problem is insufficient functional ADAMTS13 itself.

What About HUS and Other TMAs?

Reduced ADAMTS13 activity can occur in a number of illnesses, including other thrombotic microangiopathies and severe systemic disease.

The important distinction is severe deficiency.

An activity below 10% is strongly associated with TTP, whereas patients with complement-mediated HUS, Shiga toxin-associated HUS, HELLP syndrome, malignant hypertension, transplant-associated TMA, and many other causes of microangiopathic hemolysis generally do not demonstrate the profound ADAMTS13 deficiency characteristic of TTP.

This is one reason ADAMTS13 testing has become so important in the evaluation of patients presenting with thrombocytopenia and MAHA.

Should TTP Patients Receive Platelets?

Generally, no—not prophylactically simply because the platelet count is extremely low.

TTP is fundamentally a thrombotic disorder in which platelets are already being consumed in platelet-rich microthrombi. Routine platelet transfusion has therefore traditionally been avoided because of concern that additional platelets could contribute to ongoing microvascular thrombosis.

Platelet transfusion may still be appropriate in exceptional circumstances, particularly life-threatening or critical-site bleeding, with the decision based on the clinical situation rather than the platelet count alone.

Treatment of Immune TTP

TTP was historically associated with extremely high mortality. Modern treatment has dramatically changed its prognosis, but rapid recognition and treatment remain essential.

Current therapy for acute immune TTP generally attacks the disease from several directions at once.

Therapeutic Plasma Exchange

Therapeutic plasma exchange (TPE) remains a central treatment for acute immune TTP.

During TPE, the patient's plasma is removed and replaced with donor plasma. This provides functional ADAMTS13 while simultaneously removing circulating anti-ADAMTS13 autoantibodies and other pathogenic plasma components.

This is more than simply giving plasma. Plasma exchange allows large amounts of the patient's antibody-containing plasma to be removed while repeatedly replacing ADAMTS13.

TPE is generally performed daily during the acute phase, with treatment continued according to the patient's platelet recovery, hemolysis, clinical response, and the overall treatment protocol.

It is not simply a matter of reaching a platelet count of 150,000/µL and automatically stopping.

Corticosteroids

Because most acquired TTP is autoimmune, corticosteroids are used to suppress the immune response responsible for producing anti-ADAMTS13 antibodies.

Corticosteroids are generally used alongside plasma exchange rather than as an alternative to it.

Rituximab

Rituximab is a monoclonal antibody directed against CD20 on B lymphocytes.

By reducing the B-cell population, rituximab suppresses production of the autoantibodies responsible for ADAMTS13 deficiency.

Rituximab is commonly incorporated into treatment of immune TTP and is also used in selected patients during remission when ADAMTS13 activity falls and the risk of relapse increases.

Caplacizumab

One of the biggest changes in modern TTP treatment has been the introduction of caplacizumab.

Caplacizumab targets the A1 domain of VWF and prevents its interaction with platelet glycoprotein Ib. In other words, while plasma exchange and immunosuppression address the underlying ADAMTS13 deficiency and autoantibody, caplacizumab rapidly interrupts the VWF-platelet interaction responsible for the microvascular thrombosis.

This can rapidly improve thrombocytopenia and reduce continued formation of platelet-rich microthrombi while the underlying autoimmune disease is brought under control.

Current treatment strategies for acute immune TTP therefore commonly combine:

Plasma exchange + corticosteroids + caplacizumab, with rituximab frequently added for immunosuppression.

Treatment of Congenital TTP

Congenital TTP is different because there is no autoimmune inhibitor to remove.

Historically, treatment relied primarily on plasma infusion to replace the missing ADAMTS13 enzyme.

That changed with the development of recombinant ADAMTS13.

ADAMTS13, recombinant-krhn (Adzynma) is an enzyme-replacement therapy approved for both prophylactic and on-demand treatment of congenital TTP in adults and children.

Instead of supplying ADAMTS13 indirectly through donor plasma, recombinant ADAMTS13 replaces the deficient enzyme directly.

This represents a major shift in the management of congenital TTP and avoids many of the limitations associated with repeated plasma infusions.

ADAMTS13 Is Also Useful After the Acute Episode

ADAMTS13 isn't useful only for making the initial diagnosis.

In patients with immune TTP, ADAMTS13 activity can remain severely reduced or fall again even after the platelet count and hemolysis have normalized.

Persistently or recurrently low ADAMTS13 activity during clinical remission can indicate an increased risk of relapse. Monitoring ADAMTS13 activity can therefore help identify patients who may benefit from additional immunosuppressive treatment before another full clinical episode develops.

The Takeaway

ADAMTS13 normally keeps highly adhesive VWF multimers under control.

When ADAMTS13 activity becomes severely deficient, ultralarge VWF multimers remain in circulation and recruit platelets, producing widespread platelet-rich microthrombi. Platelets are consumed, red blood cells are fragmented in the microcirculation, and organ ischemia can rapidly develop.

In immune TTP, the problem is usually an autoantibody against ADAMTS13. Treatment therefore combines replacement and removal through plasma exchange, suppression of the autoimmune response, and—with caplacizumab—direct interruption of VWF-mediated platelet adhesion.

In congenital TTP, the underlying problem is inherited ADAMTS13 deficiency, and recombinant ADAMTS13 now allows direct enzyme replacement.

A protein with an absurdly long name turns out to be one of the most important regulators preventing normal hemostasis from turning into uncontrolled microvascular thrombosis.

Read More

Duffy The Vampire Slayer?

Duffy Null (Fya-Fyb-) and Malaria

 The prevailing thought was that Duffy negative (Fya-Fyb-) phenotypes typically found throughout the African population confer a level of immunity, protection, against Plasmodium vivax (and Plasmodium knowlesi) infection typically spread through Anopheles mosquito encounters.

 Nearly 75% of African descended humans have the Duffy negative phenotype Fya- Fyb-. Some populations and regions of Africa may have an even higher prevalence of such phenotype. The significance of this is...much like sickled cells are thought to provide protection against Plasmodium falciparum infection, lacking the Duffy antigen system is thought to provide protection against Plasmodium vivax infection, considering P. vivax uses the Duffy antigen system as a vector for infection.

 Duffy negative phenotype carriers (Fya-Fyb-) will typically carry a "silent" Fy-b allele. However, it does not get expressed on red blood cells due to a mutation that causes an encoding failure within the Erythroid Transcription Factor or "GATA-1". This produces a red cell that fails to carry and express the Fy-b antigen. It is highly unlikely that a patient would develop Anti-Fyb, because Fyb would still be expressed throughout other bodily tissues. Thus, the immune system recognizes the Fyb antigen as part of 'self'. For transfusion purposes, most transfusion centers would consider the patient to be Fyb positive *for transfusion purposes* and could receive Fyb positive blood. It is very unlikely the patient would mount a reaction to Fyb+ red cells. There is an even more rare mutation that does cause complete lack of Duffy antigen throughout the body

The Duffy antigen, known, wholly as DARC or Duffy Antigen Chemokine Receptor (shouldn't that be DACR then??) acts as a receptor for the parasite to invade the cell and begin the stages of infection. For decades of time it was believed this gave full protection over Plasmodium infection. Unfortunately, this is not the full case. As time went on and more studies are taken on, it is being noticed that Fya/Fyb patients do have Plasmodium infection. If anything, it appears there could be less severe infection with noticeable asymptomatic carriers of the disease in Duffy negative patients. It is possible that with time, Plasmodium will mutate further and cause considerably more damage in Duffy negative patients. 

More studies are still needing to look into this play between Duffy and Plasmodium. Don't try to load up on Duffy negative blood before traveling to endemic areas... that would be silly.

Read More

Platelet Additive Solution (PAS) Platelets and Their Variations

Platelet Additive Solutions: What's the Difference Between PAS-A, PAS-B, PAS-C and the Rest?

Maybe you're used to seeing PAS-C platelets and haven't given much thought to the letter after "PAS." But PAS isn't one single formulation. Over the years, several platelet additive solutions have been developed with different combinations of citrate, acetate, phosphate, potassium, magnesium, gluconate, glucose, and other components.

So what are these solutions actually doing, and why are there so many versions?

What Are Platelet Additive Solution (PAS) Platelets?

Traditionally, platelets are stored primarily in the donor's plasma. Platelet additive solutions (PAS) allow a substantial portion of that plasma to be replaced with a crystalloid storage solution while maintaining platelet viability and function.

For example, FDA-approved Isoplate platelets are stored in approximately 65% PAS and 35% plasma. InterSol is likewise designed to replace a substantial portion of the plasma in stored apheresis platelets.

The remaining plasma is important. It provides nutrients—including glucose in many systems—and contributes to an environment in which platelets can remain viable during storage.

Why Use PAS?

Reducing the amount of donor plasma has several advantages.

Less ABO-Incompatible Plasma

Platelets express ABO antigens, but another important issue with platelet transfusion is the donor plasma contained in the unit.

For example, a group O platelet may contain anti-A and anti-B capable of reacting with a non-O recipient's red cells. PAS replaces much of that plasma and therefore substantially dilutes donor ABO antibodies.

Studies have demonstrated significantly lower anti-A and anti-B titers in PAS platelets compared with platelets stored entirely in plasma.

That can make ABO-nonidentical platelet transfusion easier to manage.

It does not, however, mean that ABO compatibility suddenly becomes irrelevant.

PAS units still contain residual donor plasma, and hemolytic reactions from ABO-incompatible PAS platelets have been reported. Whether PAS platelets require isoagglutinin titers or other restrictions therefore depends on the blood supplier, product, patient population, and transfusion-service policy.

Fewer Plasma-Mediated Reactions

Reducing plasma also reduces exposure to donor plasma proteins.

PAS platelets have been associated with lower rates of allergic transfusion reactions compared with conventional plasma-stored platelets. In one study of PAS-C platelets, allergic reactions were significantly reduced compared with plasma-stored apheresis platelets.

PAS also reduces the concentration of other plasma constituents, including donor HLA antibodies. That may theoretically reduce some plasma-mediated risks, but PAS should not be considered a method that completely removes these antibodies or eliminates the possibility of TRALI.

Why Do Platelets Need All These Chemicals?

Platelets are metabolically active during storage.

They consume substrates, produce lactate, undergo membrane changes, and gradually develop the platelet storage lesion. A good additive solution has to provide an appropriate osmotic environment while supporting metabolism and limiting excessive acidification and platelet activation.

Different PAS formulations approach that problem differently.

The letters PAS-A through PAS-G describe broad compositional categories, not simply brand names and not necessarily a straightforward sequence in which every later letter is universally "better."

PAS-A

Major components: citrate, phosphate, and potassium

PAS-A represents an early approach to platelet additive solutions.

These early formulations demonstrated that platelets could be stored with substantially less plasma, but platelet metabolism and maintenance of an acceptable pH remained major limitations.

Later generations incorporated acetate and other components to improve metabolic conditions during storage.

PAS-B

Major components: citrate and acetate

Examples have included T-Sol, SSP, and PAS-II.

One of the major developments in PAS-B was the incorporation of acetate.

Platelets can oxidize acetate as an energy substrate. Acetate metabolism also helps reduce the degree of acidification that would otherwise result from continued glycolysis and lactate production.

This improves maintenance of pH during storage.

PAS-B formulations were an important step forward, but later solutions added additional buffering and electrolytes to further improve platelet storage characteristics.

PAS-C

Major components: citrate, phosphate, and acetate

The best-known PAS-C product in the United States is InterSol, also historically referred to as PAS-III. InterSol is FDA approved for partial replacement of plasma during storage of compatible apheresis platelet products.

Compared with PAS-B, the addition of phosphate provides additional buffering capacity, helping maintain an appropriate pH as platelet metabolism continues during storage.

PAS-C has also been extensively used with pathogen-reduction systems.

Because of its widespread use, PAS-C is probably the PAS formulation many American blood bankers are most likely to recognize by name—particularly InterSol.

PAS-D

Major components: citrate, phosphate, acetate, magnesium, potassium, and gluconate

An example is Composol.

PAS-D introduced magnesium and potassium, which became important additions in later platelet additive solutions.

Experimental studies demonstrated that adding magnesium and potassium can reduce platelet activation during storage and improve several measures of platelet function.

Gluconate is also included in PAS-D formulations.

It is sometimes described as primarily a calcium-chelating ingredient, but that is an oversimplification. Its role depends on the formulation; in modern PAS formulations containing gluconate, it also contributes to the solution's ionic and buffering environment.

PAS-E

Major components: citrate, phosphate, acetate, magnesium, and potassium

Examples include SSP+ and T-PAS+.

PAS-E essentially combines the buffering characteristics of phosphate-containing PAS with the beneficial effects of magnesium and potassium on platelet activation and metabolism.

Studies comparing magnesium- and potassium-containing solutions with earlier PAS formulations have generally demonstrated improved in-vitro platelet characteristics during storage.

SSP+ and T-PAS+ are both classified as PAS-E even though their exact formulations are not completely identical. A 2024 head-to-head study found them sufficiently similar in platelet-storage performance despite small compositional differences.

Depending on the particular system and regulatory approval, PAS-E formulations may permit replacement of an even greater proportion of plasma. SSP+, for example, has been used with approximately 80% PAS and 20% plasma in approved settings outside the United States.

PAS-F

PAS-F formulations incorporate acetate, magnesium, potassium, and additional buffering components, with the precise composition depending on the product.

A particularly important U.S. example is Isoplate, which the FDA classifies as PAS-F.

Isoplate contains:

• sodium chloride

• sodium acetate

• potassium

• magnesium

• phosphate

• sodium gluconate

FDA-approved Isoplate platelet products contain approximately 65% Isoplate and 35% plasma.

The FDA describes acetate as supporting platelet metabolism, phosphate and gluconate as contributing to buffering, and magnesium and potassium as helping reduce platelet activation.

This is a useful example of why the PAS letters are better thought of as compositional families rather than perfectly rigid recipes.

PAS-G

PAS-G represents another experimental generation of platelet additive solutions and generally incorporates:

citrate, phosphate, acetate, magnesium, potassium, and glucose.

The addition of glucose directly to the PAS is particularly important conceptually.

Many earlier PAS formulations depend on the residual plasma fraction to provide glucose. Adding glucose directly to the additive solution creates the possibility of reducing the amount of plasma even further while still supplying an important metabolic substrate.

PAS-G has also been studied as a medium for reconstituting cryopreserved platelets. Experimental work found good platelet recovery when frozen platelets were thawed and reconstituted in PAS-G.

What About M-Sol?

M-Sol should not simply be listed as another name for PAS-G.

M-Sol is a separate experimental platelet storage formulation developed from clinically available solutions. It shares several concepts with later-generation PAS formulations—including magnesium, potassium, and glucose—but has its own composition.

This illustrates another problem with PAS nomenclature: commercial products, experimental formulations, historical PAS numbers, and modern PAS letter categories do not always map neatly onto one another.

So Why Not Remove 100% of the Plasma?

If reducing plasma is beneficial, why not eliminate it entirely?

Because PAS has to do more than simply dilute the plasma.

Platelets need an appropriate supply of metabolic substrates, electrolytes, buffering capacity, osmotic balance, and other conditions that maintain their function during storage.

In many commonly used PAS formulations, residual plasma remains an important source of glucose and other components. If too much plasma is removed without replacing those functions, platelet metabolism and storage quality deteriorate.

More advanced formulations—including glucose-containing solutions—have been developed partly to allow further reductions in residual plasma.

But there is currently no universal "100% PAS" product that has replaced conventional PAS/plasma mixtures in routine platelet transfusion practice.

The Takeaway

PAS platelets aren't simply "platelets with less plasma."

The composition of the additive solution affects platelet metabolism, activation, buffering, and storage characteristics.

Early formulations primarily established that plasma could be replaced. Later formulations introduced acetate for metabolic support, phosphate for buffering, magnesium and potassium to reduce platelet activation, and eventually glucose and other components intended to support storage with progressively less plasma.

From the transfusion-service side, the reduced plasma volume also brings practical benefits: fewer allergic reactions and substantially reduced exposure to donor ABO antibodies.

But PAS does not make platelet ABO compatibility irrelevant and does not completely eliminate plasma-associated transfusion risks.

So when you see PAS-C, PAS-E, or PAS-F on a platelet product, that little letter actually represents quite a bit of platelet-storage chemistry.

Read More

Is Blood a Drug?

Is Blood a Drug?

Yes—at least in the regulatory sense.

Blood and blood components occupy an interesting place in U.S. law because the FDA regulates them both as biological products and as drugs. The two major federal statutes involved are the Public Health Service Act and the Federal Food, Drug, and Cosmetic Act (FD&C Act).

That doesn't mean a unit of RBCs is treated exactly like a bottle of lisinopril sitting in the pharmacy.

Blood is a biologic: a complex product obtained from a human donor, collected, tested, processed, stored, labeled, distributed, and ultimately transfused into another person. FDA's Center for Biologics Evaluation and Research (CBER) regulates blood and blood components intended for transfusion and establishes standards governing their manufacture and safety.

And yes, in the eyes of federal law, blood components also fall within the regulatory framework applied to drugs.

Blood Is a Manufactured Product

One of the strange things about working in a blood bank is that we don't usually think of ourselves as working in manufacturing.

But from the FDA's perspective, that's exactly what much of blood banking is.

The regulatory definition of manufacturing encompasses much more than collecting a bag of blood. Testing, processing, preparation, labeling, storage, holding, and distribution can all fall within the manufacturing framework governing blood products. FDA consequently applies current Good Manufacturing Practice requirements specifically to blood and blood components.

Think about everything that has to happen before an RBC unit reaches a patient's IV:

A donor must meet eligibility requirements.

The donation has to be collected properly.

Required infectious-disease testing must be performed.

The component must be prepared correctly.

Its ABO/RhD type and other required information must be correct.

Storage temperature has to remain within specification.

Expiration dating has to be correct.

Any required modification—such as irradiation—has to occur.

The correct product has to be selected for the correct patient.

Compatibility testing has to be performed appropriately.

And the unit has to remain traceable throughout the entire process.

FDA oversight reaches across this system. CBER establishes and enforces standards for blood collection and manufacturing, inspects blood establishments, and monitors errors, accidents, and adverse events involving blood products.

Why Are Blood Banks So Obsessed With Documentation?

This helps explain one of the first things new blood bankers learn:

If it wasn't documented, it didn't happen.

Blood products exist inside a tightly controlled manufacturing and distribution system. Procedures aren't merely suggestions for how the technologist on duty prefers to perform a task. The blood bank has validated procedures describing how products are tested, prepared, modified, stored, selected, labeled, and issued.

When something deviates from those procedures, it may need to be investigated and documented.

That doesn't mean every mistake automatically gets reported to the FDA.

FDA's Biological Product Deviation reporting requirements apply to certain deviations or unexpected events involving manufacturing, testing, processing, labeling, storage, holding, or distribution when a distributed product may have had its safety, purity, or potency affected. Reportable events must generally be submitted as soon as possible and no later than 45 calendar days after the establishment obtains information indicating that a reportable event occurred.

If a problem is discovered and corrected before the affected product is distributed, FDA guidance specifically notes that it may require internal investigation and documentation without necessarily requiring a Biological Product Deviation Report.

So the real rule is closer to:

Investigate deviations. Document them. Then determine whether the event meets FDA reporting criteria.

What Does a Reportable Blood Bank Error Actually Look Like?

This isn't just theoretical.

FDA publishes summaries of Biological Product Deviation Reports submitted by transfusion services. In fiscal year 2023, transfusion services submitted reports involving:

• products that were not irradiated when irradiation was required

• incorrect ABO or RhD product selection

• incorrect product selection

• outdated products

• failures involving compatibility testing

• antibody-screen or antibody-identification errors

• antigen-typing errors

• ABO/RhD testing errors

• incorrect or incomplete transfusion-service labeling.

In fact, FDA's FY2023 report recorded 126 transfusion-service reports involving a product that was not irradiated as required.

So imagine a patient has a documented requirement for irradiated cellular blood components.

The blood bank accidentally issues a nonirradiated unit.

The unit is transfused.

That isn't merely, "Oops, someone forgot to click the irradiated box."

A product that failed to meet the patient's required specifications was distributed and transfused. The blood bank has to investigate what happened, determine why its safeguards failed, assess the affected product and patient, and determine the applicable FDA reporting obligations.

That is one reason transfusion services build so many layers of computer warnings, historical attributes, special-requirement flags, product checks, SOPs, and second checks around seemingly simple tasks.

Does Every Hospital Blood Bank Get FDA Inspections?

There's another nuance here.

Not every hospital transfusion service is required to register with FDA. A transfusion service operating within a CLIA-certified facility that performs compatibility testing and transfusion but does not routinely collect or process blood products may qualify for an exemption from FDA blood-establishment registration.

Blood establishments that manufacture blood products are generally subject to FDA registration requirements, and licensed manufacturers face additional federal requirements.

So saying simply, "Every blood bank is FDA inspected because blood is a drug" isn't quite right.

But FDA regulation absolutely reaches deeply into transfusion medicine, including the manufacturing and distribution requirements governing blood components and the reporting obligations that can apply to hospital transfusion services.

What About Physician Orders?

Blood components are not treated like ordinary over-the-counter supplies that anyone can simply request from the laboratory.

Hospitals require appropriate clinical authorization for transfusion, and transfusion services have procedures governing routine orders, emergency release, massive transfusion protocols, and other urgent circumstances.

However, saying:

"Blood is legally a drug, therefore federal law requires a physician's prescription before the blood bank can release it"

isn't the best way to explain the relationship.

FDA's classification of blood components as drugs and biologics primarily drives requirements surrounding manufacture, safety, purity, potency, labeling, storage, distribution, and regulatory oversight.

The exact requirements for who may order or authorize transfusion—and how emergency transfusion is documented—also depend on hospital procedures, professional standards, accreditation requirements, and applicable state law.

That's why emergency-release RBCs can be issued before compatibility testing is complete when the clinical situation demands it. The process isn't "no paperwork, no blood." Rather, the transfusion service follows a specifically established emergency procedure that documents who authorized the transfusion and acknowledges the additional risk.

From Donor to Recipient

FDA oversight of blood begins long before a technologist receives a type-and-screen specimen.

It encompasses donor eligibility and screening, infectious-disease testing, collection, component preparation, storage, labeling, and distribution. FDA also regulates many of the products used to make this system work, including blood-collection systems, donor-testing assays, apheresis equipment, pathogen-reduction technology, and blood-establishment computer software.

That helps explain why transfusion medicine can sometimes feel less like a typical clinical laboratory department and more like a tiny pharmaceutical manufacturing operation hidden inside a hospital.

Every unit has a manufacturing history.

Every unit has defined storage requirements.

Every unit has an expiration date.

Every unit has labeling requirements.

Every unit must be traceable.

And when something goes wrong, the response can extend far beyond simply correcting a result in the LIS.

Blood may come from another human being, but once it enters the blood-supply system, it becomes one of the most tightly controlled biological products used in medicine.

Read More